The Breakthrough Spravato Treatment for Medication-Resistant Depression
Find Relief Through Spravato® Nasal Spray
Available Now at Geode Health in Illinois, Texas and Georgia – Call (888) 902-1704 to Learn More
Geode Health is proud to offer Spravato®
Are you struggling with treatment-resistant depression and have tried multiple antidepressants with no success? Depression affects your overall mental health…but Geode Health is here to help.
With Spravato®, many treated patients have experienced significant improvements in their depression symptoms in as little as four weeks. Plus, it’s covered by most major insurance providers.
Geode Health is proud to offer Spravato® treatment at several Geode Health locations across Illinois, Texas and Georgia. Don’t wait any longer to feel relief from persistent depression. Call today or book online with a Geode healthcare provider to start feeling better sooner.
Spravato® Is Now Available at the Following Geode Locations:
- Chicago (West Town), IL
- Rockford, IL
- Libertyville, IL
- Flower Mound, TX
- Fort Worth, TX
- Stafford, TX
- Athens, GA
- Suwanee, GA
Frequently Asked Questions About Spravato®
Spravato®, a nasal spray form of the medication esketamine, is used in conjunction with an oral antidepressant to treat certain cases of major depressive disorder (MDD), a form of depression. Spravato® is FDA-approved for use in adults with depression who have not responded to other treatments, or those who have depression with thoughts of self-harm or acute suicidal ideation.
At Geode, your safety is our top priority. While Spravato® can be an appropriate treatment for severe depression, all treated patients at Geode must be able to maintain safety in the community. If you are having active suicidal thoughts or feeling unsafe, please seek help immediately at a crisis treatment center or hospital.
Spravato® is an NMDA receptor antagonist, meaning that it attaches to and blocks NMDA receptors in the brain. This raises levels of the neurotransmitter glutamate, leading to downstream processes that ultimately increase the growth and connectivity of brain cells (neurons).
Unlike many other medications for depression, Spravato® does not appear to work by inhibiting the reuptake of serotonin, norepinephrine, or dopamine. The precise way that Spravato® exerts its antidepressant medication effects remains under investigation.
Esketamine is one form of the combination medicine ketamine. Ketamine treatment is widely used in medicine for anesthesia and has also been used as a party drug. However, the doses of esketamine used to treat depression are much lower, and Spravato® is given in a controlled environment. Furthermore, esketamine treatment is more potent than ketamine, meaning that a lower dose can be given and side effects can be reduced. The dose and form of esketamine delivered in Spravato® can sometimes induce dissociation, but is not high enough to produce intoxication or anesthesia.
A Spravato® treatment program consists of a series of treatments administered in your Geode provider’s office. After the medication is administered intranasally, trained staff will monitor you for at least two hours to ensure there are no serious side effects.
With Spravato® depressive treatment, most patients can expect their depressive symptoms to improve quickly. In some cases, patients may even experience symptom relief within a few hours of their first treatment.
Spravato® treatments are typically administered twice a week for four weeks. After this period, your Geode provider may reduce the frequency of treatments or conclude them altogether. The duration and frequency of Spravato® treatment will depend on your depressive symptoms and response to treatment.
Common side effects of Spravato® include nausea, dizziness, headache, and increased blood pressure. Spravato® can also cause sedation and dissociation, which is a feeling of detachment from oneself and one’s surroundings. Because of these risks, patients are monitored for at least two hours at the treatment center after the medication is administered.
Spravato® is approved by the FDA for use in adults with treatment-resistant depression or major depressive disorder with thoughts of self-harm or suicide. However, Spravato® is not for everyone, and it is important to talk with your healthcare provider to see if it is the right treatment option for you.
Good Candidates for Spravato® Treatment
You may be a good candidate for Spravato® treatment if you meet the following criteria:
- You have been diagnosed with major depressive disorder or treatment-resistant depression.
- You have not responded to other forms of treatment such as psychotherapy, antidepressant medications, and/or lifestyle changes.
- You have major depressive disorder with self-harm or suicidal thoughts of self-harm or acute suicidal ideation but are able to maintain your own safety in the community. Depending on the severity of these thoughts, patients may require hospitalization.
- You are 18 years old or older.
- You are willing to comply with the safety measures recommended by your Geode provider.If you meet the criteria above and think Spravato® may be a good treatment option for you, talk to your Geode provider. They can evaluate your overall mental health issues or depression symptoms and give you more information about how Spravato® or other treatment options can help manage your depression.